This content is restricted.
Brief
"On October 12, 2024, the Federal Trade Commission issued an update regarding Statement on FTC's Win in Lawsuit Against the Makers of Dietary Supplement Prevagen. The U.S. District Court for the Southern District of New York ordered Quincy Bioscience to cease making deceptive claims about Prevagen that mislead Americans concerned about memory loss. This ruling marks another win in the FTC's efforts to protect older Americans and promote reliable scientific evidence behind health claims."
Highlights content goes here...
This content is restricted.

RADA.AI
Hello! I'm RADA.AI - Regulatory Analysis and Decision Assistance. Your Intelligent guide for compliance and decision-making. How can i assist you today?
Suggested